152 related articles for article (PubMed ID: 27563839)
1. Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.
Rockberg J; Amelio JM; Taylor A; Jörgensen L; Ragnhammar P; Hansson J
Int J Cancer; 2016 Dec; 139(12):2722-2729. PubMed ID: 27563839
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
[TBL] [Abstract][Full Text] [Related]
3. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Eur J Cancer; 2013 Aug; 49(12):2705-16. PubMed ID: 23583439
[TBL] [Abstract][Full Text] [Related]
4. Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.
Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J
J Clin Oncol; 2014 May; 32(13):1356-64. PubMed ID: 24687828
[TBL] [Abstract][Full Text] [Related]
5. Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register.
Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1468-1474. PubMed ID: 28419674
[TBL] [Abstract][Full Text] [Related]
6. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
7. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma.
Poo-Hwu WJ; Ariyan S; Lamb L; Papac R; Zelterman D; Hu GL; Brown J; Fischer D; Bolognia J; Buzaid AC
Cancer; 1999 Dec; 86(11):2252-8. PubMed ID: 10590365
[TBL] [Abstract][Full Text] [Related]
8. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
9. Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study.
Utjés D; Lyth J; Lapins J; Eriksson H
Int J Cancer; 2017 Dec; 141(11):2243-2252. PubMed ID: 28799271
[TBL] [Abstract][Full Text] [Related]
10. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma.
Helvind NM; Brinch-Møller Weitemeyer M; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
JAMA Dermatol; 2023 Nov; 159(11):1213-1222. PubMed ID: 37650576
[TBL] [Abstract][Full Text] [Related]
11. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous malignant melanoma show geographic and socioeconomic disparities in stage at diagnosis and excess mortality.
Strömberg U; Peterson S; Holmberg E; Holmén A; Persson B; Sandberg C; Nilbert M
Acta Oncol; 2016 Aug; 55(8):993-1000. PubMed ID: 26935355
[TBL] [Abstract][Full Text] [Related]
13. Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
Schoffer O; Schülein S; Arand G; Arnholdt H; Baaske D; Bargou RC; Becker N; Beckmann MW; Bodack Y; Böhme B; Bozkurt T; Breitsprecher R; Buchali A; Burger E; Burger U; Dommisch K; Elsner G; Fernschild K; Flintzer U; Funke U; Gerken M; Göbel H; Grobe N; Gumpp V; Heinzerling L; Kempfer LR; Kiani A; Klinkhammer-Schalke M; Klöcking S; Kreibich U; Knabner K; Kuhn P; Lutze S; Mäder U; Maisel T; Maschke J; Middeke M; Neubauer A; Niedostatek A; Opazo-Saez A; Peters C; Schell B; Schenkirsch G; Schmalenberg H; Schmidt P; Schneider C; Schubotz B; Seide A; Strecker P; Taubenheim S; Wackes M; Weiß S; Welke C; Werner C; Wittekind C; Wulff J; Zettl H; Klug SJ
BMC Cancer; 2016 Dec; 16(1):936. PubMed ID: 27919243
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: a single-center retrospective study of 71 cases.
Zhu H; Dong D; Li F; Liu D; Wang L; Fu J; Song L; Xu G
Int J Dermatol; 2015 Dec; 54(12):1390-5. PubMed ID: 26016703
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma.
Posther KE; Selim MA; Mosca PJ; Stanley WE; Johnson JL; Tyler DS; Seigler HF
Ann Surg Oncol; 2006 May; 13(5):728-39. PubMed ID: 16538415
[TBL] [Abstract][Full Text] [Related]
16. Previous pregnancy is a favourable prognostic factor in women with localised cutaneous melanoma.
Vihinen P; Vainio-Kaila M; Talve L; Koskivuo I; Syrjänen K; Pyrhönen S
Acta Oncol; 2012 May; 51(5):662-8. PubMed ID: 22486294
[TBL] [Abstract][Full Text] [Related]
17. Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
Lyth J
Melanoma Res; 2018 Dec; 28(6):637-640. PubMed ID: 29994850
[TBL] [Abstract][Full Text] [Related]
18. Stage I cutaneous malignant melanoma: risk factors of loco-regional recurrence after wide local excision and clinical perspectives.
Bachaud JM; Shubinski R; Boussin G; Chevreau C; David JM; Viraben R; Bonafé JL; Daly NJ
Eur J Surg Oncol; 1992 Oct; 18(5):442-8. PubMed ID: 1426294
[TBL] [Abstract][Full Text] [Related]
19. The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
Eriksson H; Lyth J; Andersson TM
Int J Cancer; 2016 Jun; 138(12):2829-36. PubMed ID: 26815934
[TBL] [Abstract][Full Text] [Related]
20. A prospective population-based study of cutaneous malignant melanoma of the head and neck.
Gillgren P; Månsson-Brahme E; Frisell J; Johansson H; Larsson O; Ringborg U
Laryngoscope; 2000 Sep; 110(9):1498-504. PubMed ID: 10983950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
